Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koen Van Besien

Showing results (31-40 of 241) with videos related to

Pageof 25
Sort By:
Expert Opinion on Biological Therapy|June 28, 2011
Alemtuzumab in allogeneic hematopoetic stem cell transplantationXavier Poiré, Koen van Besien
Leukemia & Lymphoma|December 16, 2014
Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly malignedJavier Segovia, Koen van Besien
Leukemia & Lymphoma|December 28, 2020
Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantationMarkus Plate, Koen van Besien
Leukemia & Lymphoma|June 27, 2019
Tocilizumab, in search for a role in acute GVHDUsama Gergis, Koen van Besien
Leukemia & Lymphoma|June 27, 2019
Donor graft genotypes versus leukemiaHannah K Choe, Koen van Besien
JAMA|April 15, 2010
The next frontier for stem cell transplantation: finding a donor for allLucy A Godley, Koen van Besien
Leukemia & Lymphoma|July 4, 2018
A renaissance for autologous transplantation in follicular lymphoma?Ok-Kyong Chaekal, Koen van Besien
Cytotherapy|March 21, 2015
Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cellsCaroline A Lindemans, Koen van Besien
Leukemia & Lymphoma|September 14, 2020
Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?Ok-Kyong Chaekal, Koen van Besien
Leukemia & Lymphoma|November 25, 2021
Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match!Alexandra Gomez-Arteaga, Koen van Besien
Pageof 25

Showing results (31-40 of 241) with videos related to

Sort By:
Pageof 25
Expert Opinion on Biological Therapy|June 28, 2011
Alemtuzumab in allogeneic hematopoetic stem cell transplantationXavier Poiré, Koen van Besien
Leukemia & Lymphoma|December 16, 2014
Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly malignedJavier Segovia, Koen van Besien
Leukemia & Lymphoma|December 28, 2020
Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantationMarkus Plate, Koen van Besien
Leukemia & Lymphoma|June 27, 2019
Tocilizumab, in search for a role in acute GVHDUsama Gergis, Koen van Besien
Leukemia & Lymphoma|June 27, 2019
Donor graft genotypes versus leukemiaHannah K Choe, Koen van Besien
JAMA|April 15, 2010
The next frontier for stem cell transplantation: finding a donor for allLucy A Godley, Koen van Besien
Leukemia & Lymphoma|July 4, 2018
A renaissance for autologous transplantation in follicular lymphoma?Ok-Kyong Chaekal, Koen van Besien
Cytotherapy|March 21, 2015
Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cellsCaroline A Lindemans, Koen van Besien
Leukemia & Lymphoma|September 14, 2020
Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?Ok-Kyong Chaekal, Koen van Besien
Leukemia & Lymphoma|November 25, 2021
Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match!Alexandra Gomez-Arteaga, Koen van Besien
Pageof 25